The Technical Analyst
Humanigen, Inc. [HGEN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Humanigen, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-84.62% $0.0002
America/New_York / 4 jan 2024 @ 13:45
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0238 mill |
| EPS: | -0.510 |
| P/E: | -0.0004 |
| Earnings Date: | Mar 28, 2024 |
| SharesOutstanding: | 119.08 mill |
| Avg Daily Volume: | 0.342 mill |
| RATING 2024-01-16 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0004 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0004 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0009 - 0.0011 ( +/- 1 000.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-18 | Chappell Dale | Sell | 276 210 | Common Stock, $0.001 par value |
| 2023-10-18 | Chappell Dale | Sell | 75 887 | Common Stock, $0.001 par value |
| 2023-10-18 | Chappell Dale | Sell | 34 253 | Common Stock, $0.001 par value |
| 2022-07-27 | Buxton Cheryl | Buy | 78 362 | Stock Option (Right to Buy) |
| 2022-07-27 | Hohneker John | Buy | 63 195 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 39.08 |
| Last 98 transactions |
| Buy: 5 830 886 | Sell: 2 957 610 |
Forecast:
01:40 - $-0.0030
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0002 (-84.62% ) |
| Volume | 2.06 mill |
| Avg. Vol. | 0.342 mill |
| % of Avg. Vol | 603.69 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HGEN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HGEN
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Latest Press Releases
2024-03-05 12:15:00 - Press Release
Levi & Korsinsky, Llp Notifies Shareholders Of Humanigen, Inc. (hgen) An Upcoming Claims Deadline In A Class Action Settlement
New york, ny / accesswire / march 5, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against humanigen, inc. (nasdaq:hgen). the settlement provides for a fund of $3,000,000 to benefit class members.
2024-02-29 12:30:00 - Press Release
Levi & Korsinsky, Llp Notifies Shareholders Of Humanigen, Inc. (hgen) An Upcoming Claims Deadline In A Class Action Settlement
New york, ny / accesswire / february 29, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against humanigen, inc. (nasdaq:hgen). the settlement provides for a fund of $3,000,000 to benefit class members.
2023-08-07 08:01:00 - Press Release
Humanigen Announces First Participant Dosed In Rating Trial Of Lenzilumab For Early Treatment Of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
The rating (risk adapted therapy in acute gvhd) is the first trial to explore granulocyte-macrophage colony-stimulating factor (gm-csf) neutralization for the early treatment of participants with high-risk acute graft versus host disease planned interim assessment expected in 2024 following treatment of first 20 participants short hills, new jersey--(newsfile corp. - august 7, 2023) - humanigen, inc. (otc pink: hgen), a clinical-stage biopharmaceutical company, today announced successful dosing of the first participant in the rating trial of lenzilumab for the early treatment of acute graft versus host disease (agvhd), conducted by impact, a world-class accelerated clinical trial network delivering innovative research for stem cell transplant patients in major centers in the uk...
2023-06-09 12:05:00 - Press Release
Humanigen Presents Promising New Hematologic Data From Preach-m Trial For Chronic Myelomonocytic Leukemia Treatment At The 2023 European Hematology Association Congress
Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response building upon previously reported positive clinical responses, these additional data demonstrate statistically significant and clinically relevant improvements in hematologic outcomes, along with improvements in inflammatory markers, that occur in the early months after treatment initiation and appear durable cmml is a rare, aggressive cancer; approximately 20% of patients survive three years from diagnosis no new cmml medications with novel mechanisms of action have been approved in over 30 years and hypomethylating agents, such as azacitidine alone, are currently considered "standard of care" short hills, new jersey--(newsfile corp...
2023-04-14 12:05:00 - Press Release
Humanigen - Lenzilumab Being Studied As A Potential First Treatment In Thirty Years With A Novel Mechanism Of Action For Chronic Myelomonocytic Leukemia (cmml), An Orphan Form Of Leukemia
Cmml is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosis eleven subjects dosed with lenzilumab and with current standard of care, azacitidine six evaluable subjects, including those with high risk cmml, demonstrated clinical benefit at three months follow-up lenzilumab appears to be well-tolerated short hills, new jersey and adelaide, south australia--(newsfile corp. - april 14, 2023) - humanigen, inc. (nasdaq: hgen), humanigen australia pty ltd, (humanigen) and the south australian health and medical research institute (sahmri) today presented (poster ct085/13); the design and baseline results of the precision approach to chronic myelomonocytic leukemia (preach-m) study of lenzilumab in chronic myelomonocytic leukemia (cmml), at the 2023 annual meeting of the american association of cancer research being held in orlando, fl april 14-19...
Latest News
2024-01-05 11:30:17 - InvestorPlace
HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy
Humanigen (OTCMKTS: HGEN ) stock is falling hard on Friday after the company filed for Chapter 11 bankruptcy protection. This bankruptcy filing comes after Humanigen failed to secure regulatory approval for its Covid-19 treatment lenzilumab.
2024-01-04 18:54:42 - Reuters
COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy
Drug developer Humanigen HGEN.PK has filed for voluntary Chapter 11 bankruptcy, according to a court filing, after struggling to get regulatory approval for its COVID-19 treatment.
2023-07-28 11:34:01 - Proactive Investors
Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy
Humanigen Inc shares have plummeted more than 90% over the past month, and now trades at a little over a penny per share, after the clinical-stage biopharmaceutical company said it is facing bankruptcy after negotiations for a reverse merger with an unnamed, privately-held biopharma company ended. Humanigen noted that it is unable to find another source of financing that would allow it to maintain its Nasdaq listing, including a minimum share price of $1, and it is now trading on OTC Pink Market.
2023-07-25 08:29:09 - InvestorPlace
Why Is Humanigen (HGEN) Stock Down 72% Today?
Humanigen (NASDAQ: HGEN ) stock is falling hard on Tuesday after the company warned investors it can't keep listing requirements. According to a filing from the company, it is no longer compliant with Nasdaq listing standards.
2023-04-17 13:43:13 - Zacks Investment Research
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.
2023-04-14 12:38:13 - PennyStocks
3 Hot Penny Stocks To Watch Today; Is It Time To Buy?
2022-10-24 21:21:48 - 24/7 Wall Street
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
2022-09-07 06:55:00 - Newsfile Corp
Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022
Short Hills, New Jersey--(Newsfile Corp. - September 7, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab ("LENZ®"), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor ("GM-CSF"), today announced presentation and participation in two healthcare focused investor conferences in September 2022. Details of the presentation and panel participation are as follows:H.C.
2022-08-29 09:03:13 - InvestorPlace
Why Is Humanigen (HGEN) Stock Down 16% Today?
Source: shutterstock.com/PhotobyTawat Humanigen (NASDAQ: HGEN ) stock is heading lower on Monday as investors react to a delisting notice from the Nasdaq Exchange. According to a filing with the U.S. Securities and Exchange Commission (SEC), HGEN stock has been unable to maintain the minimum bid price of $1 per share to remain on the market.
2022-08-12 18:48:09 - Zacks Investment Research
Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates
Humanigen Inc. (HGEN) delivered earnings and revenue surprises of -26.47% and 0.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?